Literature DB >> 80921

Drug-induced neutropenia in the Stockholm region 1973-75: frequency and causes.

P Arneborn, J Palmblad.   

Abstract

The records of 133 patients, discharged with a diagnosis of "agranulocytosis" (i.e. blood neutrophil levels less than 1.0 x 109/1) during the years 1973-75 in the Stockholm county region, were reviewed. In 45 cases the neutropenia was probably caused by drugs other than cytostatics, giving an annual incidence of drug-induced neutropenia of 0.01%. The most common drugs were thenalidine, sulfonamides and thyreostatics. Only one of the 45 patients died during the neutropenic phase. It is concluded that the pattern of drugs causing neutropenia has changed in Sweden compared with studies from the latter half of the 1960's, and only about 40% of the cases have been reported to the authorities.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 80921     DOI: 10.1111/j.0954-6820.1978.tb08439.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  5 in total

1.  Epidemiological evaluation of rare side-effects of mild analgesics.

Authors:  M Levy
Journal:  Br J Clin Pharmacol       Date:  1980-10       Impact factor: 4.335

2.  Tardive dyskinesia associated with metoclopramide.

Authors:  B E Wiholm; O Mortimer; G Boethius; J E Häggström
Journal:  Br Med J (Clin Res Ed)       Date:  1984-02-18

3.  Glibenclamide-associated hypoglycaemia: a report on 57 cases.

Authors:  K Asplund; B E Wiholm; F Lithner
Journal:  Diabetologia       Date:  1983-06       Impact factor: 10.122

4.  The design of a study of the drug etiology of agranulocytosis and aplastic anemia. A report from the International Agranulocytosis and Aplastic Anemia Study.

Authors: 
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 5.  Idiosyncratic drug-induced haematological abnormalities. Incidence, pathogenesis, management and avoidance.

Authors:  W N Patton; S B Duffull
Journal:  Drug Saf       Date:  1994-12       Impact factor: 5.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.